Descriptions of patients and triggers
| Patients characteristics | ||||
| Description | Mean±SD | |||
| Sex ratio | 1:0.45 (127 male, 57 female) | |||
| Age | 66.5±13.2 years | |||
| Length of stay | 8.4±5.9 days | |||
| Trigger distribution and PPV | ||||
| Trigger | LPVr | HCQ | P value | PPV |
| At least one drug–drug interaction | 59 (67.0%) | 77 (59.2%) | 0.26 | 12.5% (17/136) |
| QTc interval >499 ms or QT interval prolongation >49 ms | 19 (21.6%) | 30 (23.1%) | 1.0 | 32.6% (16/49) |
| Hypokalaemia | 2 (2.3%) | 21 (16.2%) | 10−3 | 8.3% (2/24) |
| Hypomagnesaemia | 0 (0.0%) | 2 (1.5%) | 0.5 | 100% (2/2) |
| LPVr wrong dose | 8 (9.1%) | 0 (0%) | 10−4 | 100% (8/8) |
| Total | 88 | 130 | – | 20.6% |
| Therapeutic classes involved in drug-drug interactions distribution | ||||
| Therapeutic classes involved in drug–drug interactions | % (n) | |||
| Antipsychotics (haloperidol, quetiapine, etc) | 20.5% (42) | |||
| Antibacterials for systemic use (azithromycin, levofloxacin, etc) | 14.6% (30) | |||
| Calcium channel blockers (amlodipine, felodipine) | 11.7% (24) | |||
| β-blocking agents (metoprolol, atenolol, propranolol) | 11.7% (24) | |||
| Antithrombotic agents (acenocoumarol, clopidogrel, edoxaban, etc) | 10.7% (22) | |||
| Psychoanaleptics (citalopram, escitalopram, etc) | 7.3% (15) | |||
| Cardiac therapies (amiodarone, isosorbide dinitrate) | 3.9% (8) | |||
| Analgesics (tramadol, morphine, etc) | 3.4% (7) | |||
| Others | 16.2% (33) | |||
HCQ, hydroxychloroquine; LPVr, lopinavir/ritonavir; PPV, predictive positive value (ratio of triggers associated with an intervention divided by total interventions).